Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

IGF-1 protects against diabetic features in an in vivo model of Huntington's disease.

Duarte AI, Petit GH, Ranganathan S, Li JY, Oliveira CR, Brundin P, Björkqvist M, Rego AC.

Exp Neurol. 2011 Oct;231(2):314-9. doi: 10.1016/j.expneurol.2011.06.016. Epub 2011 Jul 7.

PMID:
21763311
2.

Impaired glucose tolerance in the R6/1 transgenic mouse model of Huntington's disease.

Josefsen K, Nielsen MD, Jørgensen KH, Bock T, Nørremølle A, Sørensen SA, Naver B, Hasholt L.

J Neuroendocrinol. 2008 Feb;20(2):165-72. Epub 2007 Nov 22.

PMID:
18034868
3.

Striatal expression of a calmodulin fragment improved motor function, weight loss, and neuropathology in the R6/2 mouse model of Huntington's disease.

Dai Y, Dudek NL, Li Q, Fowler SC, Muma NA.

J Neurosci. 2009 Sep 16;29(37):11550-9. doi: 10.1523/JNEUROSCI.3307-09.2009.

4.

Sustained striatal ciliary neurotrophic factor expression negatively affects behavior and gene expression in normal and R6/1 mice.

Denovan-Wright EM, Attis M, Rodriguez-Lebron E, Mandel RJ.

J Neurosci Res. 2008 Jun;86(8):1748-57. doi: 10.1002/jnr.21636.

5.

IGF-1 intranasal administration rescues Huntington's disease phenotypes in YAC128 mice.

Lopes C, Ribeiro M, Duarte AI, Humbert S, Saudou F, Pereira de Almeida L, Hayden M, Rego AC.

Mol Neurobiol. 2014 Jun;49(3):1126-42. doi: 10.1007/s12035-013-8585-5. Epub 2013 Dec 18.

PMID:
24347322
6.

The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.

Hickey MA, Reynolds GP, Morton AJ.

J Neurochem. 2002 Apr;81(1):46-59.

7.
8.

Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation.

Pérez-Severiano F, Escalante B, Vergara P, Ríos C, Segovia J.

Brain Res. 2002 Sep 27;951(1):36-42.

PMID:
12231454
9.

CGS21680 attenuates symptoms of Huntington's disease in a transgenic mouse model.

Chou SY, Lee YC, Chen HM, Chiang MC, Lai HL, Chang HH, Wu YC, Sun CN, Chien CL, Lin YS, Wang SC, Tung YY, Chang C, Chern Y.

J Neurochem. 2005 Apr;93(2):310-20.

10.

Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.

Hansson O, Nylandsted J, Castilho RF, Leist M, Jäättelä M, Brundin P.

Brain Res. 2003 Apr 25;970(1-2):47-57.

PMID:
12706247
11.

The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis.

Björkqvist M, Fex M, Renström E, Wierup N, Petersén A, Gil J, Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H.

Hum Mol Genet. 2005 Mar 1;14(5):565-74. Epub 2005 Jan 13.

PMID:
15649949
12.

Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington's disease: behavioral testing and impact of diabetes mellitus.

Lüesse HG, Schiefer J, Spruenken A, Puls C, Block F, Kosinski CM.

Behav Brain Res. 2001 Nov 29;126(1-2):185-95.

PMID:
11704263
13.

Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.

Naver B, Stub C, Møller M, Fenger K, Hansen AK, Hasholt L, Sørensen SA.

Neuroscience. 2003;122(4):1049-57.

PMID:
14643771
16.

Insulin and IGF-1 regularize energy metabolites in neural cells expressing full-length mutant huntingtin.

Naia L, Ribeiro M, Rodrigues J, Duarte AI, Lopes C, Rosenstock TR, Hayden MR, Rego AC.

Neuropeptides. 2016 Aug;58:73-81. doi: 10.1016/j.npep.2016.01.009. Epub 2016 Feb 3.

PMID:
26876526
17.

Hsp27 overexpression in the R6/2 mouse model of Huntington's disease: chronic neurodegeneration does not induce Hsp27 activation.

Zourlidou A, Gidalevitz T, Kristiansen M, Landles C, Woodman B, Wells DJ, Latchman DS, de Belleroche J, Tabrizi SJ, Morimoto RI, Bates GP.

Hum Mol Genet. 2007 May 1;16(9):1078-90. Epub 2007 Mar 14.

PMID:
17360721
18.

Metformin therapy in a transgenic mouse model of Huntington's disease.

Ma TC, Buescher JL, Oatis B, Funk JA, Nash AJ, Carrier RL, Hoyt KR.

Neurosci Lett. 2007 Jan 10;411(2):98-103. Epub 2006 Nov 15.

PMID:
17110029
19.

Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice.

Harris AS, Denovan-Wright EM, Hamilton LC, Robertson HA.

J Psychiatry Neurosci. 2001 Mar;26(2):117-22.

20.

The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.

Gil JM, Rego AC.

Brain Res Rev. 2009 Mar;59(2):410-31. doi: 10.1016/j.brainresrev.2008.12.001. Epub 2008 Dec 16. Review.

PMID:
19118572

Supplemental Content

Support Center